Day One Biopharmaceuticals Acquisition Rumors Spark Retail Interest
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2026
0mins
Source: stocktwits
- Significant Stock Surge: Day One Biopharmaceuticals (DAWN) shares closed 28% higher on Wednesday amid acquisition rumors, indicating strong market interest and reflecting investor optimism about the company's future prospects.
- Positive Analyst Ratings: According to Koyfin, eight out of nine analysts covering DAWN stock rate it as ‘Buy’ or higher, with only one rating it as ‘Hold’, suggesting a generally favorable outlook for the company, with an average price target of $22.75 representing over 75% potential upside.
- Retail Sentiment Soars: On Stocktwits, retail sentiment around DAWN stock remained in the ‘extremely bullish’ territory over the past 24 hours, with message volume rising from ‘high’ to ‘extremely high’, indicating increasing investor anticipation for a potential merger that could further drive stock prices up.
- Financial Performance Insights: Despite a net loss of $107.3 million in 2025, up from $95.5 million in 2024, the company expects U.S. revenue from Ojemda to reach between $225 million and $250 million in 2026, highlighting the potential and market demand for its therapies targeting life-threatening diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
